Iterum Therapeutics PLC
ITRMF Healthcare Biotechnology
In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ITRMF
Iterum Therapeutics PLC (ITRMF) Altman Z-score
Iterum Therapeutics PLC's Altman Z-score for fiscal 2019 is −26.27, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2019 | −26.27 | (23.80) |
| FY2018 | −2.47 | — |
How fiscal 2019’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.98) | — | −1.18 | |
| Retained earnings / total assets | (9.12) | — | −12.77 | |
| EBIT / total assets | (3.96) | — | −13.07 | |
| Market value of equity / total liabilities | 1.26 | — | 0.75 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −26.27 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −63.33 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| MLEC Moolec Science SA compare | −1.9× |
| SILO Silo Pharma, Inc. compare | −3.1× |
| CARM Carisma Therapeutics Inc. compare | −19.7× |
| TRVN Trevena, Inc. compare | −22.1× |
| ITRMF Iterum Therapeutics PLC | −26.3× |
| ABPO Abpro Holdings Inc. compare | −44.7× |
| NEXI NexImmune, Inc. compare | — |
| GNPX GENPREX compare | — |
| ARTL Artelo Biosciences, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets